You are here: Industry Insights > IBD

News List

Research Progress of Polyphenol Compound in the Treatment of Inflammatory Bowel Disease and Intestinal Fibrosis PharmaSources/Xiao Nisha
January 04, 2022
Polyphenol compound is a class of plant secondary metabolites and is the general term for polyhydroxy compounds. Their structure includes one or more sugar residues connected to hydroxyl groups...
Ben-Gurion University Researchers to Develop Novel Biological Treatment for Inflammatory Bowel Diseases americanpharmaceuticalreview
August 13, 2021
Researchers at Ben-Gurion University of the Negev (BGU) are developing a novel therapeutic strategy for treating Inflammatory Bowel Diseases (IBD) by sequestering inflammation-inducing molecules secreted by gut bacteria.
Takeda takes the lead on Finch's ulcerative colitis candidate FIN-524 pharmatimes
August 12, 2021
Takeda has elected to accelerate the transition of development responsibility for Finch Therapeutics' FIN-524, an investigational oral microbiome therapy in development for ulcerative colitis.
Artificial intelligence could be new blueprint for precision drug discovery worldpharmanews
July 13, 2021
Writing in the July 12, 2021 online issue of Nature Communications, researchers at University of California San Diego School of Medicine describe a new approach that uses machine learning to hunt for disease targets and then predicts whether a drug is ...
MIMETAS and Roche Enter into a Collaboration to Develop Human Disease Models for Drug Development b3cnewswire
July 07, 2021
MIMETAS announced today that they have entered into a collaboration to develop human disease models to characterize novel compounds in inflammatory bowel disease (IBD) and hepatitis B virus infections (HBV).
Lynk Pharmaceuticals Announced Clinical Approval in China of Its New Class I Drug LNK01003 prnasia
June 25, 2021
Lynk Pharmaceuticals Co., Ltd. announced today that its new Class I innovative drug LNK01003, has been approved by National Medical Products Administration (NMPA) for clinical trials of inflammatory bowel disease (IBD).
Galapagos signs deal with Scipher for IBD drug development pharmatimes
August 17, 2020
Belgium-based biotech Galapagos has signed a collaboration deal with Scipher Medicine to advance novel drug targets for the treatment of inflammatory bowel disease (IBD).
Gilead signs drug discovery deal with Second Genome pharmaceutical-technology
April 08, 2020
Gilead Sciences has entered a multi-programme agreement with Second Genome to discover targets and drug candidates for inflammatory bowel disease (IBD) treatment.
Royalty Pharma Acquires Royalties on Entyvio from Massachusetts General Hospital americanpharmaceuticalreview
March 09, 2020
Royalty Pharma has acquired Massachusetts General Hospital's (MGH) royalty interest in Entyvio (vedolizumab) for $94 million.
IBD May Increase Risk for Adverse Pregnancy Outcomes drugs
January 20, 2020
Women with inflammatory bowel disease (IBD) more often have gestational diabetes and preterm premature rupture of membranes, according to a review published online January in Alimentary Pharmacology and Therapeutics.

Previous page 1 2 3 Next page